Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
INMD · Nasdaq · United States · Electromedical & Electrotherapeutic Apparatus
In shortInMode Ltd. is profitable.
Financial health
Solid
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 23.0% | 93/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 25.3% | 100/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 13.5% | 68/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | – | n/a |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 9.88× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | – | n/a |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | – | n/a |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | – | n/a |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 18.86 | 100/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 22.7% | 100/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 0.90× | 75/100 |
| Years with positive free cash flow (last 5) | 5 of 5 | 100/100 |
Weight in the score: 20%
| Profitable years (last 5) | 5 of 5 | 100/100 |
|---|---|---|
| Years of revenue decline (last 5) | 2 of 5 | 33/100 |
| Revenue growth volatility | 36.2% | 0/100 |
| Operating margin volatility | 10.2% | 17/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | -6.6% | 0/100 |
|---|---|---|
| EPS growth, 3-year average | -8.9% | 0/100 |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
4 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 358 | 454 | 492 | 395 | 370 |
| Cost of revenue | 54 | 73 | 81 | 78 | 80 |
| Gross profit | 304 | 381 | 411 | 317 | 291 |
| Research & development | 9.5 | 12 | 13 | 13 | 13 |
| Operating income | 167 | 198 | 196 | 113 | 85 |
| Pre-tax income | 168 | 201 | 217 | 143 | 110 |
| Income tax | 2.9 | 40 | 19 | (38) | 16 |
| Net income | 165 | 162 | 198 | 181 | 94 |
| Diluted EPS | $1.92 | $1.89 | $2.30 | $2.25 | $1.43 |
| Diluted shares (millions) | 86 | 85 | 86 | 81 | 65 |
4 older years available with the 10-year history. Essential plan, from €8.25/month →
18.86 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
4/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Dec 31, 2025 · Data updated Feb 10, 2026